Clinical data | |
---|---|
Trade names | Jivi |
Other names | BAY94-9027, antihemophilic factor (recombinant), pegylated-aucl |
AHFS/ Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C7445H11318N1984O2184S69 |
Molar mass | 165774.28 g·mol−1 |
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A. [5] [6]
The most common side effects include headache, cough, nausea, and fever. [5]
Damoctocog alfa pegol was approved for medical use in the United States in August 2018, [7] and in the European Union in November 2018. [6] [8]
In the United States damoctocog alfa pegol is indicated for use in previously treated people twelve years of age and older with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; or routine prophylaxis to reduce the frequency of bleeding episodes. [7]
In the European Union, damoctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in previously treated people twelve years of age and older with hemophilia A (congenital factor VIII deficiency). [6]